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320* Longitudinal adherence to dornase alfa (Pulmozyme):
association with multiple clinical outcomes in patients with
cystic ﬁbrosis
M.S. Schwartz1, W.S. Warren1, G. Graff1. 1Pennsylvania State University/Milton
S. Hershey Medical Center, Pediatrics, Hershey, United States
Objectives: To utilize primary insurance records to calculate percent adherence to
prescribed dornase alfa among pediatric CF patients at our center in 2009 and 2010,
and to explore for associations between adherence and multiple clinical outcomes.
Methods: Prescription information for dornase alfa was obtained from multiple
insurance companies for 54 CF patients for whom dornase alfa was prescribed at
our center in 2009 and 2010. Annual percent adherence was calculated for each
patient by dividing the number of dornase alfa doses actually dispensed by the total
number of doses prescribed in each calendar year.
Results: Compared to those with adherence less than 70% in 2009, the more
adherent group (n = 24) had a 16.4 percent predicted higher FEV1 % (P = 0.006),
4.7 fewer hospitalized days (P = 0.044), and 10.9 fewer days of IV antibiotics
(P = 0.041). Compared to those with adherence less than 70% in the ﬁrst half
of 2010*, the more adherent group (n = 27) had a 14.8 percent predicted higher
FEV1% (P = .014). Those patients who had a persistently higher level of adherence
in 2009 and 2010 had a 17.1 percent predicted higher mean FEV1 % (P = 0.0047)
when compared to those who had a persistently poorer level of adherence.
Conclusions: The regular use of dornase alfa is associated with improved pul-
monary function, fewer days of hospitalization, and fewer days of IV antibiotics.
We speculate that improved adherence to dornase alfa and other therapies may result
in improved outcomes in CF, and that the percent adherence to prescribed dornase
alfa may prove to be a useful surrogate marker for the level of overall adherence
to prescribed therapies in this population.
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Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in
measurable serum levels. This could affect calculation of pharmacokinetic (PK)
parameters and dosing if TIS is used concurrently with intravenous (IV) tobramycin
for treatment of a pulmonary exacerbation. Computer PK modeling predicts that
TIS given in the latter portion of the IV dosing interval would result in increased
tobramycin trough levels in some patients. We wanted to assess the signiﬁcance
of timing of TIS on IV tobramycin trough levels in the clinical setting. Adult
CF patients infected with P. aeruginosa admitted to the hospital for treatment of
a pulmonary exacerbation were eligible for the study. IV tobramycin was dosed
every 12 hours based on previous PK measures for a planned tobramycin trough
<1mcg/ml. Tobramycin levels were drawn approximately 2 and 9 hours after a
dose. The following day, tobramycin levels were again drawn at 2 and 9 hours, but
TIS was given 5−7 hours after the IV dose. Ten patients have participated thus far.
All tolerated the IV tobramycin and TIS without any adverse effects. Seven patients
did not have a clinically signiﬁcant change in the tobramycin trough level; however
3 patients had an increase in their trough level >2mcg/ml. The creatinine remained
stable throughout the treatment in all patients.
Conclusion: Trough tobramycin levels were signiﬁcantly inﬂuenced in some (30%)
of CF patients following aerosolized TIS when given in the latter part of the
IV dosing interval. This is consistent with a signiﬁcant absorption of inhaled drug
in some patients and it will inﬂuence IV drug dosing.
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Introduction: The eFlow® rapid nebulizer is used for the nebulization of e.g.
salbutamol, colistimethate and tobramycin. While the nebulizer reservoir is designed
to be held in horizontal position, the regulatory guideline DIN EN 13544−1 requires
tests at different holding angles. This study evaluates the performance of the eFlow
rapid at the holding angles speciﬁed in the guideline.
Method: Tests at three different angles (horizontal, 15º up and 15º down) were
conducted by breath simulation (PARI Compas™ II breath simulator) with a
standardized breathing pattern (500ml TV, 15 breaths/min, in:ex = 1:1). 10 devices
were tested in triplicate, each, for three drugs and corresponding ﬁll volumes (2.5ml
Sultanol®, 4ml ColiFin® and 5ml TOBI®).
Results:When the nebulizer was tilted 15º down the Delivered Dose (DD) increased
slightly for Sultanol (28.4% vs. 25.3%) and ColiFin (40.3% vs. 37.5%). No increase
was observed for TOBI. Relative to the DD obtained at horizontal orientation, this
corresponds to an increase of 13% and 7% for Sultanol and ColiFin, respectively.
When the nebulizer was tilted 15º up the DD decreased slightly for Sultanol
(22.5% vs. 25.3%), TOBI (38.3% vs. 41.2%) and ColiFin (36.3% vs. 37.5%). This
corresponds to a relative decrease of 11%, 7% and 3% for Sultanol, TOBI and
ColiFin.
Conclusion: Delivery efﬁciency for the eFlow rapid can depend on the holding
angle. This is more pronounced for drugs with small ﬁll volumes (2.5ml Sultanol)
and less for drugs with larger ﬁll volumes (4ml ColiFin or 5ml TOBI). The
difference from the DD in horizontal position is less than 15% if the nebulizer
is kept within the holding angles speciﬁed by DIN EN 13544-1.
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Objectives: To explore the relationships between treatment satisfaction and com-
pliance with inhaled antibiotics in CF using the data from the EAGER study.
Methods: A randomized open-label clinical trial was designed to compare a
nebulized and a dry powder device for tobramycin in CF patients with chronic
Pseudomonas lung infection aged 6 years and above (N= 553). Treatment satisfac-
tion was assessed using the Treatment Satisfaction Questionnaire with Medication
(TSQM) and compliance was estimated in two ways: as a continuous variable,
percentage of treatment doses taken, and as a dichotomous variable, with a threshold
of 80% doses taken. The relationships between TSQM scores and the percentage of
doses taken were studied using linear regressions. The relationships between TSQM
scores and dichotomized compliance were studied using logistic regressions.
Results: Over the ﬁrst 4 weeks of treatment, most of the patients had very high
compliance (mean percentage of doses taken was 96.5%) and very few (5.9%) took
less than 80% of the doses. Two domain scores of the TSQM, measuring the per-
ceived impact of Side-effects and Overall satisfaction, demonstrated a statistically
signiﬁcant relationship (p< 0.05) with the percentage of doses taken. Perceived
Side-effects score was the only TSQM domain to be statistically signiﬁcantly
(p< 0.05) related to compliance in the logistic regressions.
Conclusion: Despite the restrictive features related to the clinical trial settings, an
association between satisfaction and compliance could be shown: higher patient
satisfaction and lower perceived impact of side-effects were shown to be associated
with better compliance to CF inhaled treatment.
